secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2024-06-20T23:59:59+00:00
Accession:  0001193125-24-164554
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara Biotherapeutics effects 1:25 reverse stock split effective June 20, 2024
------------------------------------------------------------------------------

- Reverse stock split ratio of 1:25 approved by board on June 10, effective June 20.
- Common stock begins trading on split-adjusted basis under new CUSIP 046513206.
- No fractional shares; cash payment based on closing price prior to effective date.
- Stockholders approved proposal at annual meeting on June 10, 2024.
- Amendment filed with Delaware Secretary of State.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000119312524164554/0001193125-24-164554-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000119312524164554/d843613d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-164554

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer